Sen. Peter Welch

Maddy summaryS 1445, the Stop Arctic Ocean Drilling Act of 2025, prohibits the U.S. government from leasing or authorizing oil and gas exploration, development, or production in Arctic areas of the outer Continental Shelf. The bill directly affects federal agencies, specifically the Secretary of the Interior, by blocking new leases or extensions for oil and gas activities in these sensitive Arctic waters. It amends the Outer Continental Shelf Lands Act to add a permanent prohibition, overriding existing laws, with the Arctic defined per the 1984 Arctic Research and Policy Act. This bill would prevent future drilling permits in the Arctic Ocean region without requiring new congressional action.

Maddy summaryThe FIGHT Act of 2025 amends the Animal Welfare Act to ban gambling on animal fighting events (including broadcasts), prohibit transporting roosters (defined as male chickens over 6 months old) for fighting, and make it illegal to sponsor, exhibit, or allow minors under 16 to attend such events. It allows citizens to file civil lawsuits to stop violations after 60 days' notice to authorities, with fines up to $5,000 per violation. The law also permits seizure of property used to facilitate violations, such as land or buildings. It does not override state or local laws on animal fighting unless there is a direct conflict.

Maddy summaryThis bill extends Medicare payment incentives for healthcare providers using alternative payment models, directly affecting Medicare participating doctors and hospitals. It updates specific years in payment formulas from 2026 to 2027 and adjusts the 2027 incentive rate from 1.88% to 3.53%. The key mechanism modifies Medicare payment rules to maintain existing financial incentives through 2028, ensuring continuity for providers participating in these models. The changes are technical amendments to the Social Security Act's Medicare provisions.

Maddy summaryThis bill (S 1481) repeals a specific provision (Section 13532 of Public Law 115-97) related to advance refunding bonds. It restores the previous rules allowing state and local governments to issue these bonds for infrastructure projects, as if the 2017 amendment had never been enacted. The change directly affects state and local governments seeking to refinance existing debt using advance refunding bonds. The bill takes effect upon enactment and does not create new funding or alter infrastructure project eligibility.

Maddy summaryThe SEER Act 2025 targets conflicts of interest among special government employees (SGEs) - temporary or part-time workers who may have outside business interests while serving in government roles. The bill requires SGEs not serving on advisory committees to publicly disclose financial conflicts, restricts their communications with agencies regarding companies they own or lead, and creates a searchable public database tracking SGE service duration and roles. It modifies financial disclosure requirements so that most SGEs must now file public reports, unlike current practice where many were exempt. The legislation affects all SGEs who aren't on advisory committees, particularly those in roles with significant decision-making authority. The bill aims to increase transparency and reduce conflicts for temporary government workers with substantial outside business interests.

Maddy summaryThis bill removes exclusions for grazing crops and grasses from the Noninsured Crop Disaster Assistance Program (NAP), expanding eligibility for disaster aid to farmers who grow these crops. Previously, farmers raising crops used for grazing were excluded from NAP benefits, but this change would allow them to access the same disaster assistance as other farmers. The Secretary of Agriculture must issue new regulations within 90 days of the bill's enactment to implement these changes. The policy directly affects ranchers and farmers who rely on grazing land for livestock, providing them with access to federal disaster support during crop failures or natural disasters.

Maddy summaryThis bill prohibits "reverse payment" agreements where brand-name drug companies pay generic or biosimilar manufacturers to delay entering the market, which harms competition. It creates a presumption that such agreements are anticompetitive if a generic or biosimilar company receives value in exchange for delaying market entry, with exceptions for standard settlements involving early market entry rights or reasonable litigation expenses. The bill amends the Federal Trade Commission Act to enforce this new prohibition and requires certification of such agreements, aiming to enhance competition and lower drug costs for consumers. This would directly affect brand-name drug companies, generic manufacturers, and biosimilar biological product manufacturers.

Maddy summaryThe Stop STALLING Act empowers the Federal Trade Commission (FTC) to take action against pharmaceutical companies that submit "sham" petitions under drug approval processes. Specifically, it targets petitions that are objectively baseless and used to delay generic drug approvals, directly affecting drug manufacturers filing such petitions. The bill establishes civil penalties of up to $50,000 per day or the revenue earned from the delayed drug during the petition's review period. It creates a presumption of "sham" status if the Health Secretary determines a petition was filed primarily to delay approval, with companies able to rebut this presumption. The law does not alter FDA drug approval rules but adds FTC enforcement for unfair competition tactics.

Maddy summaryThe provided context does not include a substantive summary or bill text beyond the short title. Without details on the bill's specific provisions, mechanisms, or affected parties, a factual summary cannot be generated. The title "Interagency Patent Coordination and Improvement Act of 2025" suggests a focus on federal patent processes, but no concrete policy changes are described in the given text. For an accurate summary, the full bill language or official summary would be required.

Maddy summaryThis bill requires the Federal Trade Commission (FTC) to study how pharmacy benefit managers (PBMs) and other intermediaries affect prescription drug prices and competition. Specifically, the FTC must report within one year on whether PBMs charge different prices to pharmacies, steer patients toward pharmacies they own, use pharmacy data for profit, or design formularies to favor expensive drugs. The bill also mandates an interim report within six months and a separate study on sole-source drug manufacturers and enforcement challenges. It does not directly change drug prices or create new regulations, but instead seeks to gather data to inform potential future policy actions. The study focuses on transparency and competition in the pharmaceutical supply chain, with no immediate price-reducing mechanisms.